stockrowGilead Sciences, Inc. (GILD) vs GSK PLC Sponsored ADR (GSK)
- Gilead Sciences, Inc. GILD 167.50 −0.04%
- GSK PLC Sponsored ADR GSK 49.85 −1.11%
Gilead Sciences, Inc. and GSK PLC Sponsored ADR are both Drug Manufacturers General companies. Gilead Sciences, Inc. is the larger, with a market value of $207.8B against $101.0B — 2.1× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; GSK PLC Sponsored ADR trades at 16.7×. GSK PLC Sponsored ADR grew revenue faster over the last twelve months: 6.90% against 6.54%. GSK PLC Sponsored ADR has the higher net margin (13.0% vs −12.5%) and the higher return on invested capital (9.61% vs −4.51%). Both pay a dividend; GSK PLC Sponsored ADR yields more (3.60% vs 1.94%). Across the 22 metrics below, GSK PLC Sponsored ADR leads on 15 and Gilead Sciences, Inc. on 7.
Valuation
Profitability
| Metric | GILD | GSK | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.93% | 72.64% | 73.01% |
| Operating margin | (7.63%) | 17.95% | 18.34% |
| Net margin | (12.47%) | 13.02% | 7.31% |
| Free cash flow margin | 44.47% | 19.65% | 18.52% |
| Return on equity | (22.45%) | 25.48% | 5.80% |
| Return on assets | (7.03%) | 6.53% | 2.28% |
| Return on invested capital | (4.51%) | 9.61% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack